Cowen reissued their buy rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report sent to investors on Thursday morning, TipRanks reports.
A number of other equities analysts have also recently issued reports on the company. Oppenheimer restated a hold rating on shares of Agios Pharmaceuticals in a report on Thursday. BMO Capital Markets increased their price target on Agios Pharmaceuticals from $45.00 to $49.00 and gave the stock an outperform rating in a report on Monday, December 9th. JPMorgan Chase & Co. restated a buy rating on shares of Agios Pharmaceuticals in a report on Friday, January 31st. Citigroup cut their price target on Agios Pharmaceuticals from $80.00 to $64.00 and set a buy rating on the stock in a report on Tuesday, November 5th. Finally, Royal Bank of Canada set a $79.00 price target on Agios Pharmaceuticals and gave the stock a buy rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $63.73.
Shares of Agios Pharmaceuticals stock traded down $0.44 on Thursday, reaching $51.57. 27,808 shares of the company’s stock were exchanged, compared to its average volume of 722,764. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.53 and a beta of 2.42. Agios Pharmaceuticals has a 52 week low of $28.36 and a 52 week high of $68.94. The firm’s 50-day moving average is $49.91 and its two-hundred day moving average is $41.14. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.24 and a current ratio of 5.30.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.12. The firm had revenue of $35.44 million for the quarter, compared to analysts’ expectations of $33.72 million. Agios Pharmaceuticals had a negative return on equity of 70.07% and a negative net margin of 356.42%. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.58) EPS. On average, analysts expect that Agios Pharmaceuticals will post -7.05 EPS for the current fiscal year.
In related news, insider Christopher Bowden sold 49,638 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $50.08, for a total value of $2,485,871.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Carman Alenson sold 2,950 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $50.09, for a total value of $147,765.50. The disclosure for this sale can be found here. 3.16% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of AGIO. Steward Partners Investment Advisory LLC lifted its holdings in shares of Agios Pharmaceuticals by 430.6% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 1,109 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 900 shares in the last quarter. First Mercantile Trust Co. bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth $44,000. Advisory Services Network LLC lifted its holdings in shares of Agios Pharmaceuticals by 1,150.0% in the 4th quarter. Advisory Services Network LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 920 shares in the last quarter. Advisor Group Inc. lifted its holdings in shares of Agios Pharmaceuticals by 551.3% in the 4th quarter. Advisor Group Inc. now owns 1,244 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,053 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in shares of Agios Pharmaceuticals by 146.5% in the 4th quarter. US Bancorp DE now owns 1,427 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 848 shares in the last quarter.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Further Reading: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.